Carcinoid syndrome occurs when a rare cancerous tumor, called a carcinoid tumor, secretes certain chemicals into your bloodstream, causing a variety of signs and symptoms.

Related: Crinetics Pharma's Investigational Candidate Shows Promise In Rare Type Of Hormonal Disorder.

Administration of paltusotine resulted in rapid and sustained reductions in bowel movement (BM) frequency and flushing episodes:

• 65% reduction of excess bowel movements (defined as daily bowel movements above the upper limit of normal, 3/day) for patients with >3/day at baseline
• 65% reduction of flushing frequency for patients with >1/day at baseline.

Paltusotine was generally well-tolerated with a safety profile consistent with prior clinical studies.

• There were no treatment-related severe or serious adverse events (AEs), with most treatment-related AEs being mild to moderate.
• The most frequently reported AEs included diarrhea, headache, and abdominal pain.

Enrollment in the study is complete, with 36 participants enrolled. Topline data from the complete study is expected in the first half of 2024.

Price Action: CRNX shares are up 10.50% at $36.75 on the last check Tuesday.